JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
13/10/26 - 13:00
Diasorin obtained FDA approval for Human Parvovirus B19 IgM and IgG on the Liaison XL (334.34 KB)
02/10/26 - 14:22
Margherita Sacerdoti appointed Investor Relations & ESG Senior Director at Diasorin (151.77 KB)
31/07/26 - 12:50
Revenue and EBITDA Supported by Strong Q2 Growth in the First Half of the Year. 2026 Guidance Confirmed. (277.39 KB)
19/06/26 - 15:45
Diasorin Announces FDA 510(K) Clearance and CLIA Waiver for the LIAISON NES Group A Streptococcus (GAS) Assay (174.02 KB)
20/05/26 - 11:16
Diasorin Board of Directors approves the 2026-2030 Business Plan (246.32 KB)
19/05/26 - 19:23
Diasorin Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal Flex Assay (179.61 KB)
08/05/26 - 17:54
Revenues and EBITDA in line with the expected quarterly revenue trend and impacted by a weak flu season. 2026 Guidance confirmed (256.38 KB)
04/05/26 - 17:45
Diasorin Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President (158.42 KB)
29/04/26 - 15:52
Shareholders' Meeting 2026 (166.06 KB)
07/04/26 - 10:05
Communication on total amount of voting rights (7 April 2026) (225.44 KB)
20/03/26 - 17:44
Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024 (349.08 KB)
19/03/26 - 9:47
Diasorin signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform (234.16 KB)
24/02/26 - 7:06
Diasorin introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN (154.8 KB)
03/02/26 - 12:13
Diasorin submits LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver (130.94 KB)
29/01/26 - 7:03
Diasorin has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL (128.56 KB)
27/01/26 - 16:05
The Shareholders' meeting authorized the purchase of treasury shares, approved the amendment of art. 5 of the articles of association and authorized the cancellation of treasury shares. The Board approved the launch of the buyback plan. (120.91 KB)
26/01/26 - 7:09
Diasorin signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel (131.63 KB)
23/01/26 - 17:49
Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer. (108.99 KB)
24/12/09 - 1:00
Financial instruments to employees (26.76 KB)
30/10/09 - 1:00
The BoD approves Q3'09 results (212.92 KB)
12/10/09 - 2:00
Strengthening of group's R&D team (99.72 KB)
08/10/09 - 2:00
2009 Financial calendar update (97.3 KB)
05/10/09 - 2:00
Financial instruments to employees (27.08 KB)
06/08/09 - 2:00
The BoD approves H1'09 results (214.79 KB)
08/06/09 - 2:00
2009 Financial calendar update (97.33 KB)
18/05/09 - 2:00
Financial instruments to employees (26.65 KB)
10/04/09 - 2:00
Corporate Governance Report at December 2008. (97.57 KB)
08/04/09 - 2:00
2009 Financial calendar update (103.88 KB)
19/03/09 - 1:00
The BoD approves FY 2008 results (221.59 KB)
20/02/09 - 1:00
Financial instruments to employees (26.39 KB)
13/02/09 - 1:00
The BoD approves Q4'08 results (170.79 KB)
28/01/09 - 1:00
2009 Financial calendar (93.96 KB)
08/01/09 - 1:00